Galapagos Announces Last Patient Has Been Randomized in Crohn’s Disease Study With Filgotinib

Galapagos Announces Last Patient Has Been Randomized in Crohn’s Disease Study With Filgotinib
Galapagos NV a clinical-stage biotechnology company specializing in the discovery and development of small molecule medicines with novel modes of action, recently announced the last patient randomisation in their Phase 2 clinical trial for Crohn's disease called FITZROY. The trial is assessing the safety and efficacy of filgotinib,Janus kinase inhibitor with selectivity for subtype JAK1 of this enzyme. It is considered a promising agent as it inhibits JAK1 selectively. The study involves 20 weeks of treatment with the drug in 175 patients with a diagnosis of Crohn's disease. Filgotinib is the first drug that inhibits JAK1 selectively for the treatment of Crohn's disease. This Phase 2 clinical trial is evaluating the induction of disease remission and also exploring early maintenance of filgotinib effects. Based on the results, the drug agent could rapidly enter into Phase 3 clinical trials. Galapagos is funding and conducting the trial. Patient recruitment was sought from 66 centers across 9 countries in Eastern and Western Europe. The company is expecting to announce the study's primary endpoint results after 10 weeks of treatment in December, and 20-week treatment results during the first trimester of 2016. The Phase 2 clinical trial of filgotinib for the treatment of Crohn's disease is being conducted in parallel with the DARWIN Phase 2B
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *